Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 11/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.56 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609961 | 0.82 | — | — | |
| SCHEMBL12609963 | 0.82 | — | — | |
| SCHEMBL4389764 | 0.81 | EPHA2 (0.85) | EPHA2KDREPHB4FLT1 | |
| SCHEMBL907248 | 0.77 | EPHA2 (1.00) | EPHA2KDREPHB4 | |
| SCHEMBL13590264 | 0.77 | EPHA2 (1.00) | EPHA2KDREPHB4 | |
| SCHEMBL5467825 | 0.77 | EGFR (1.00) | KDREGFRLCKFLT1GAK | |
| SCHEMBL28946210 | 0.76 | EGFR (0.51) | EPHA2KDREPHB4EGFR | |
| SCHEMBL28798391 | 0.75 | EGFR (0.57) | EPHA2KDREPHB4EGFR | |
| Hydrochloric Acid SCHEMBL5479908 | 0.75 | EGFR (0.97) | KDREGFRLCKFLT1GAK | |
| SCHEMBL28798384 | 0.75 | EPHA2 (0.49) | EPHA2KDREPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | EPHA2 4566/4885KDR 970/4885EPHB4 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.